Dopaminomimetic psychosis in Parkinson's disease patients: Diagnosis and treatment

Neurology

Volumn 52, Issue 7 SUPPL., 1999, Pages

  Wolters, Erik Ch ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR;

AGRANULOCYTOSIS; CLINICAL TRIAL; CORPUS STRIATUM; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC SYSTEM; HUMAN; LIMBIC SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SOMNOLENCE; TARDIVE DYSKINESIA;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0033594423     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Wolters E.Ch, Francot Ch. Mental dysfunction in Parkinson's disease. Parkinsonism Relat Dis 1998;4:107-112.
2. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
3. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-497.
4. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 995;15(Suppl 1):11-18.
5. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pk1 values. J Pharmacol Exp Ther 1989; 251:238-246.
6. Auzou P, Ozsancak C, Hannequin D, Moore N, Augustin P. Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand 1996;94:329-336.
7. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995;16:270-275.
8. Van Tol HHM, Bunzow JR, Guan H, et al. Cloning of the gene for human dopamine D-4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
9. Amt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology 1998;18:63-101.
10. Wolters ECh, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40:832-834.
11. Friedman JH, Lannon MC, Stewart RL, et al. Low dose clozapine for the treatment of drug-induced psychosis (DIP) in idiopathic Parkinson's disease (PD): results of the double blind, placebo-controlled PSYCLOPS Trial [abstract]. Neurology 1998;50(Suppl 4):A70.
12. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multi-centered clinical experience. Mov Disord 1998;13:377-382.
13. Alvir JMA, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
14. Ford B, Lynch TC, Greene P. Risperidone in Parkinson's disease. Lancet 1994;344:681.
15. Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994;343:1370-1371.
16. Workman RH, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurol Sci 1997;9:594-597.
17. Rosebush PI, Mazurek MF. Extrapyramidal side effects of risperidone [abstract]. Neurology 1997;48(Suppl):A325.
18. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75.
19. Juncos JL, Evatt ML, Jewart D. Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998;50(Suppl 4):A70-71.
20. Rosenfeld MJ, Friedman JH, Jacques C. Quetiapine Pilot Trial in Dopamimetic Psychosis (DP) in Parkinson's disease (PD). Mov Disord 1998;13(Suppl 2):242.
21. Wolters ECh, Jansen ENH, Tuynman-Qua HG, Bergmans PML. Olanzapine in the treatment of dopaminometic psychosis in patients with Parkinson's disease. Neurology 1996;47: 1085-1087.
22. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50:1195-1196.
23. Tollefson GD, Beasly CM, Tamura RN. Blind, controlled, long-term study of comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254.
24. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology 1997;17:407-418.
25. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995;45:1305-1308.
26. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996;47:1608-1609.